Cerebral small vessel disease (CSVD) may benefit from anti-inflammatory therapy, as age-related inflammation—mediators such as TNF, caspase-1, IL-1β, and the NLRP3 inflammasome—is considered a risk factor (25, 27). Here, NLRP3 is linked to cerebral small vessel disease.